SCHEMBL4869370

SCHEMBL4869370

Cc1ccc(S(=O)(=O)c2cc(O)c(O)c(C(=O)O)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.50
ALDH1A1 P00352 3/20 0.49
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
COMT P21964 1/20 0.48
CSNK2A1 P68400 1/20 0.46
MCL1 Q07820 3/20 0.45
CTDSP1 Q9GZU7 2/20 0.44
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
STAT3 P40763 1/20 0.44
SIRT5 Q9NXA8 1/20 0.44
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44
LMNA P02545 2/20 0.44
PKM P14618 1/20 0.44
PHLPP2 Q6ZVD8 1/20 0.43
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132949 0.88 PHLPP2 (0.52) GAAALDH1A1HSD17B10KDM4EHPGD
SCHEMBL7514015 0.86 MCL1 (0.52) GAAALDH1A1HSD17B10KDM4EHPGD
SCHEMBL5153485 0.85 GAA (0.64) GAAALDH1A1COMTL3MBTL1PKM
SCHEMBL4861734 0.84 GAA (0.46) GAAALDH1A1COMTPOLBLMNA
SCHEMBL8962291 0.83 APEX1 (0.60) GAAALDH1A1KDM4EMCL1CTDSP1
SCHEMBL15745644 0.79 GAA (0.55) GAAALDH1A1KDM4ECTDSP1POLB
SCHEMBL9304667 0.77 HTT (0.59) GAAMCL1CTDSP1POLBAPEX1
SCHEMBL5153996 0.76 GAA (0.52) GAAALDH1A1KDM4ECOMTPOLB
SCHEMBL4120980 0.76 BCL2L1 (0.59) ALDH1A1HSD17B10KDM4EHPGDPOLB
SCHEMBL4129021 0.76 PHLPP2 (0.50) ALDH1A1HSD17B10KDM4EHPGDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 GAA 110/4885ALDH1A1 46/4885HSD17B10 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.